A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Inclusion Criteria: * Documented locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable (dose-escalation stage only) * Documented locally advanced or metastatic NSCLC in patients who have failed at least one prior chemotherapy-based regimen for incurable disease (cohort-expansion stage only) * Adequate organ function as assessed by laboratory tests * Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST) * Agreement to use an effective form of contraception for the duration of the study Exclusion Criteria: * Any anti-cancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy) within a specified timeframe prior to first study treatment * Prior treatment with PI3K pathway-inhibiting agents (cohort-expansion stage only) * History of Grade \>= 3 fasting hyperglycemia or diabetes requiring regular medication * Current clinically significant and uncontrolled systemic disease (e.g., cardiovascular, pulmonary, or metabolic) * History of clinically significant cardiac or pulmonary dysfunction * History of malabsorption syndrome or other condition that would interfere with enteral absorption * Clinically significant history of liver disease * Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agents * Active autoimmune disease and/or need for corticosteroid therapy * Known brain metastases that are untreated, symptomatic, or require therapy * Pregnancy, lactation, or breastfeeding